20 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
N=649 N=355 N= 448 Acute kidney injury 100% Septic shock 100 % Septic shock: 20% - 43% 28 - days mortality range 23 - 30% 25 - 32% 23 - 30%
17
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
to databases, and laws and regulations in regard of slander;
24. Claims by any third party suffering any personal injury and/or bodily injury
6-K
EX-99.2
e3bp2 9769ds8
6 Dec 18
Amended Notice of Annual and Extraordinary General Meeting of the Shareholders
4:43pm
20-F
dtua15jna
31 Mar 15
Annual report (foreign)
12:00am
424B4
594 792meuhu
31 Jul 14
Prospectus supplement with pricing info
12:00am
F-1/A
gxavo 9z0
8 Jul 14
Registration statement (foreign) (amended)
12:00am
- Prev
- 1
- Next